Gain Therapeutics (NASDAQ:GANX) Price Target Cut to $8.00 by Analysts at HC Wainwright

Gain Therapeutics (NASDAQ:GANX) had its price objective dropped by research analysts at HC Wainwright from $9.00 to $8.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock.

GANX has been the subject of several other research reports. Oppenheimer reissued an “outperform” rating and issued a $9.00 price target on shares of Gain Therapeutics in a research note on Tuesday, April 23rd. Chardan Capital reiterated a “buy” rating and set a $6.00 price target on shares of Gain Therapeutics in a report on Wednesday, March 27th.

Gain Therapeutics Stock Performance

Gain Therapeutics stock opened at $1.12 on Tuesday. The business has a 50 day moving average of $2.28 and a 200-day moving average of $3.28. The company has a market capitalization of $20.22 million, a P/E ratio of -0.75 and a beta of 0.35. Gain Therapeutics has a 1 year low of $1.11 and a 1 year high of $5.33. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.77 and a quick ratio of 2.77.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.08. On average, equities research analysts predict that Gain Therapeutics will post -1.11 earnings per share for the current year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.